EGFR and non-small cell lung carcinoma: In addition, the phase 3 RCT ADAURA [11, 12] assessed the efficacy and safety of 3-year osimertinib treatment versus a placebo in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC and showed the dramatic benefit in this setting with a 4-year DFS rate of 73% and a 5-year OS rate of 88%.